Skip to main content
. 2019 Dec 30;16(1):60–65. doi: 10.3988/jcn.2020.16.1.60

Table 1. Baseline characteristics according to GGT quartiles.

GGT quartile Q1 (n=195) Q2 (n=237) Q3 (n=224) Q4 (n=224) p
Sex 0.41
 Male 123 (63.1) 132 (55.7) 138 (61.6) 132 (58.9)
 Female 72 (36.9) 105 (44.3) 86 (38.4) 92 (41.1)
Age, years 72.0 [64.0–78.0] 71.0 [61.0–77.0] 68.0 [60.0–75.0] 67.0 [59.0–75.0] 0.001
BMI, kg/m2 22.6 [20.7–24.5] 23.1 [21.2–25.3] 23.8 [22.0–26.0] 23.7 [21.7–26.1] <0.001
Initial systolic blood pressure, mm Hg 157.0 [133.0–179.5] 153.0 [138.0–174.0] 150.0 [130.5–171.0] 150.0 [130.0–175.0] 0.33
Fasting blood glucose, mg/dL 98.0 [85.0–117.0] 98.0 [88.0–122.0] 100.0 [88.0–124.5] 107.0 [90.5–132.0] 0.002
Total cholesterol, mg/dL 170.0 [141.5–200.5] 171.0 [147.0–198.0] 175.0 [146.0–198.5] 176.0 [147.0–205.0] 0.52
AST, IU/L 19.0 [15.5–23.0] 21.0 [18.0–27.0] 24.0 [19.0–31.0] 30.0 [22.0–43.5] <0.001
ALT, IU/L 14.0 [10.0–18.0] 16.0 [13.0–23.0] 20.0 [15.0–30.0] 27.5 [17.0–45.5] <0.001
GGT, IU/L 13.0 [11.0–17.0] 21.0 [17.0–24.0] 32.0 [29.0–37.5] 68.0 [52.5–99.5] <0.001
Previous stroke 34 (17.4) 58 (24.5) 45 (20.1) 36 (16.1) 0.12
Hypertension 126 (64.6) 168 (70.9) 161 (71.9) 151 (67.4) 0.35
Diabetes 67 (34.4) 79 (33.3) 74 (33.0) 85 (37.9) 0.68
Hyperlipidemia 56 (28.7) 71 (30.0) 86 (38.4) 79 (35.3) 0.11
Liver disease 17 (8.7) 35 (14.8) 33 (14.7) 53 (23.7) <0.001
Smoking history 65 (33.3) 85 (35.9) 86 (38.4) 89 (39.7) 0.54
AF 19 (9.7) 34 (14.3) 35 (15.6) 44 (19.6) 0.04
NIHSS score at admission 4 [2–8] 4 [2–10] 4 [2–9] 5 [2–11] 0.17
TOAST classification 0.01
 LAA 78 (40.0) 82 (34.6) 88 (39.3) 68 (30.4)
 SVO 34 (17.4) 42 (17.7) 27 (12.1) 27 (12.1)
 CE 40 (20.5) 74 (31.2) 71 (31.7) 85 (37.9)
 UD 43 (22.1) 39 (16.5) 38 (17.0) 44 (19.6)

Data are n (%) or median [interquartile range] values.

AF: atrial fibrillation, ALT: alanine aminotransferase, AST: aspartate aminotransferase, BMI: body mass index, CE: cardioembolism, GGT: gamma-glutamyl transferase, LAA: large-artery atherosclerosis, NIHSS: National Institutes of Health Stroke Scale, SVO: small-vessel occlusion, TOAST: Trial of ORG 10172 in Acute Stroke Treatment, UD: undetermined.